1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Vaccine Contract Manufacturing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Vaccine Contract Manufacturing Market, by Vaccine Type
8.1.1 Attenuated
8.1.1.1. Market Revenue and Forecast
8.1.2. Inactivated
8.1.2.1. Market Revenue and Forecast
8.1.3. Subunit-based
8.1.3.1. Market Revenue and Forecast
8.1.4. Toxoid-based
8.1.4.1. Market Revenue and Forecast
8.1.5. DNA-based
8.1.5.1. Market Revenue and Forecast
9.1. Vaccine Contract Manufacturing Market, by Workflow
9.1.1. Downstream
9.1.1.1. Market Revenue and Forecast
9.1.2. Upstream
9.1.2.1. Market Revenue and Forecast
9.1.3. Electrolyte
9.1.3.1. Market Revenue and Forecast
9.1.4. Separator
9.1.4.1. Market Revenue and Forecast
9.1.5. Others
9.1.5.1. Market Revenue and Forecast
10.1. Vaccine Contract Manufacturing Market, by Application
10.1.1. Human Use
10.1.1.1. Market Revenue and Forecast
10.1.2. Veterinary
10.1.2.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Vaccine Type
11.1.2. Market Revenue and Forecast, by Workflow
11.1.3. Market Revenue and Forecast, by Application
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Vaccine Type
11.1.4.2. Market Revenue and Forecast, by Workflow
11.1.4.3. Market Revenue and Forecast, by Application
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Vaccine Type
11.1.5.2. Market Revenue and Forecast, by Workflow
11.1.5.3. Market Revenue and Forecast, by Application
11.2. Europe
11.2.1. Market Revenue and Forecast, by Vaccine Type
11.2.2. Market Revenue and Forecast, by Workflow
11.2.3. Market Revenue and Forecast, by Application
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Vaccine Type
11.2.4.2. Market Revenue and Forecast, by Workflow
11.2.4.3. Market Revenue and Forecast, by Application
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Vaccine Type
11.2.5.2. Market Revenue and Forecast, by Workflow
11.2.5.3. Market Revenue and Forecast, by Application
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Vaccine Type
11.2.6.2. Market Revenue and Forecast, by Workflow
11.2.6.3. Market Revenue and Forecast, by Application
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Vaccine Type
11.2.7.2. Market Revenue and Forecast, by Workflow
11.2.7.3. Market Revenue and Forecast, by Application
11.3. APAC
11.3.1. Market Revenue and Forecast, by Vaccine Type
11.3.2. Market Revenue and Forecast, by Workflow
11.3.3. Market Revenue and Forecast, by Application
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Vaccine Type
11.3.4.2. Market Revenue and Forecast, by Workflow
11.3.4.3. Market Revenue and Forecast, by Application
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Vaccine Type
11.3.5.2. Market Revenue and Forecast, by Workflow
11.3.5.3. Market Revenue and Forecast, by Application
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Vaccine Type
11.3.6.2. Market Revenue and Forecast, by Workflow
11.3.6.3. Market Revenue and Forecast, by Application
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Vaccine Type
11.3.7.2. Market Revenue and Forecast, by Workflow
11.3.7.3. Market Revenue and Forecast, by Application
11.4. MEA
11.4.1. Market Revenue and Forecast, by Vaccine Type
11.4.2. Market Revenue and Forecast, by Workflow
11.4.3. Market Revenue and Forecast, by Application
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Vaccine Type
11.4.4.2. Market Revenue and Forecast, by Workflow
11.4.4.3. Market Revenue and Forecast, by Application
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Vaccine Type
11.4.5.2. Market Revenue and Forecast, by Workflow
11.4.5.3. Market Revenue and Forecast, by Application
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Vaccine Type
11.4.6.2. Market Revenue and Forecast, by Workflow
11.4.6.3. Market Revenue and Forecast, by Application
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Vaccine Type
11.4.7.2. Market Revenue and Forecast, by Workflow
11.4.7.3. Market Revenue and Forecast, by Application
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Vaccine Type
11.5.2. Market Revenue and Forecast, by Workflow
11.5.3. Market Revenue and Forecast, by Application
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Vaccine Type
11.5.4.2. Market Revenue and Forecast, by Workflow
11.5.4.3. Market Revenue and Forecast, by Application
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Vaccine Type
11.5.5.2. Market Revenue and Forecast, by Workflow
11.5.5.3. Market Revenue and Forecast, by Application
12.1. Lonza
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Ajinomoto Althea, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Merck KgaA
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Cytovance Biologics
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Catalent, Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. IDT Biologika GmbH
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Albany Molecular Research, Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. PRA Health Sciences
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. ICON plc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
